Recruiting

Biorepository

Sponsor:

Children's Hospital Los Angeles

Code:

NCT04959097

Conditions

Retinoblastoma

Retinoblastoma Bilateral

Retinoblastoma Unilateral

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed.

Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.

Conditions

Retinoblastoma

Retinoblastoma Bilateral

Retinoblastoma Unilateral

Study ID

NCT04959097

Start date

Jan 1, 2017

Status verified date

Apr, 2026

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Dec 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All patients, age 0 days to 18 years, with a diagnosis unilateral or bilateral retinoblastoma (RB) seen at CHLA (Children's Hospital Los Angeles).

Exclusion Criteria:

  • Patients referred for second opinions only and not treated at CHLA for any reason.

Study Design

Enrollment

800 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Correlation of Ocular Salvage (eye saved) with biomarkers [ Time Frame: through study completion, a minimum of 12 months after diagnosis and average of 24 months ]
  • Identification of RB1 (RB Transcriptional Corepressor 1) gene mutations from the AH liquid biopsy [ Time Frame: through study completion, a minimum of 12 months after diagnosis and average of 24 months ]

Central Contacts and Locations

Central contacts

Jesse L Berry, MD

323-361-4510jberry@chla.usc.edu

Locations

Phoenix Children's Hospital

Recruiting

Phoenix, Arizona, United States, 85016

Contacts

Jennifer Nguyen

jnguyen5@phoenixchildrens.com

Principal Investigator:

Merrylees Dersch, MD

Children's Hospital Los Angeles

Recruiting

Los Angeles, California, United States, 90027

Contacts

Jesse Berry, MD

323-361-4510jberry@chla.usc.edu

Emory University Children's Healthcare of ATL

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Sarinee Juntipwong

404-778-4611sarinee.juntipwong2@emory.edu

Principal Investigator:

Hans Grossniklaus, MD

Ann & Robert H. Lurie Children's Hospital of Chicago

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Hanta Ralay-Ranaivo

HRalay@luriechildrens.org

Principal Investigator:

Janice Lasky-Zeid, MD

Oregon Health & Science University: Casey Eye Institute

Recruiting

Portland, Oregon, United States, 97239

Contacts

Ann Lundquist

lundquia@ohsu.edu

Principal Investigator:

Alison Skalet, M.D., Ph.D

Wills Eye Institute

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Principal Investigator:

Carol Shields, MD

St. Jude Children's Research Hospital

Recruiting

Memphis, Tennessee, United States, 38105

Contacts

Dana Hawkins

dana.hawkins@stjude.org

Principal Investigator:

Matthew Wilson, MD

Seattle Children's Hospital; University of Washington

Recruiting

Seattle, Washington, United States, 98101

Contacts

Jeff Stevens

Jeff.Stevens@seattlechildrens.org

Principal Investigator:

Andrew Stacey, M.D., M.S

The Hospital for Sick Children (Toronto SickKids)

Recruiting

Toronto, Ontario, Canada, M5G 2L3

Contacts

Roxanne Noronha

roxanne.noronha@sickkids.ca

Principal Investigator:

Brenda Gallie, MD, FRCSC, CM, OOnt

More Information

Sponsor

Children's Hospital Los Angeles

Last update posted

Apr 22, 2026

Last verified

Apr, 2026

Keywords

  • Retinoblastoma
  • RB
  • Ocular oncology
  • Aqueous humor

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Children's Hospital Los Angeles on 2026-04-22.